Conference Coverage
Latest News
Induction chemotherapy in first line improves survival for locally advanced cervical cancer
With similar results reported for pembrolizumab, a question has arisen about how to incorporate induction chemotherapy and pembrolizumab into a...
Conference Coverage
Ocular MALT lymphoma: Radiation reduces relapse
Mortality rates from early-stage ocular MALT lymphoma are low, with relapse rates lowered by radiation therapy.
Conference Coverage
Frontline myeloma treatments: ASCT vs. CAR T
Experts debate whether CAR T-cell therapy could eventually replace autologous stem cell transplant (ASCT) as the standard of care for multiple...
Conference Coverage
Dato-DXd trumps chemo in advanced HR+/HER2– breast cancer
The antibody-drug conjugate datopotamab deruxtecan had better efficacy and safety than chemotherapy for patients with endocrine-resistant...
Conference Coverage
‘Why did I choose this?’ Tackling burnout in oncology
Building a sustainable oncology workforce will not be easy, but improving staffing shortages and integrating resilience training can help, experts...
Conference Coverage
Enfortumab vedotin/pembrolizumab hailed as new standard for upfront mUC
After decades of stagnation, an almost doubling of life expectancy has set a new bar for the first-line treatment of locally advanced/metastatic...
Conference Coverage
The sobering facts about alcohol and cancer
An ESMO session highlights the well-known links between alcohol consumption and cancer and calls on healthcare professionals to do more to raise...
Conference Coverage
Chemo-immunotherapy good, adding a PARP inhibitor better in endometrial cancer?
Dr. Tan noted, the AtTEnd data "continue to validate practice-changing therapy for dMMR endometrial cancer patients."
Conference Coverage
ALK inhibitor alectinib shows DFS benefit in early NSCLC
Interim findings from the ALINA trial show improved DFS with alectinib in the adjuvant setting vs. chemotherapy in resected stage IB-IIIA NSCLC....
Conference Coverage
Perioperative nivolumab improves EFS in resectable NSCLC
Interim findings from CheckMate 77T show an overall improvement in event-free survival with perioperative nivolumab vs. neoadjuvant nivolumab plus...